Obesity

AbbVie Launches Bold Entry into Obesity Treatment with Gubra Acquisition

3 days ago

In a significant move to broaden its portfolio and tap into the burgeoning obesity treatment market, pharmaceutical giant AbbVie has announced a strategic deal with Danish biotech firm Gubra, potentially worth up to $2.2 billion. This collaboration marks AbbVie's ambitious entry into a sector that has seen a surge in demand as obesity rates continue to rise globally.

UK Biotech Startup Ventures to Challenge Weight Loss Giants Novo and Lilly

2 months ago

A new player has entered the weight loss arena, taking aim at pharmaceutical powerhouses such as Novo Nordisk and Eli Lilly. This innovative UK biotech startup has unveiled ambitious plans to develop treatment alternatives that could potentially disrupt the current market dominated by these industry leaders.

Novo Nordisk's Tough Month Causes Ripple Effect, Halts Health Stocks' Winning Streak

5 months ago

Of late, Novo Nordisk A/S, the powerhouse behind pharmaceuticals, has been facing hard times that eventually affected the broader health sector. This happens after health stocks had witnessed a record streak of gains.